Youn Hee Kim, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kim’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G58071 · Current
Licensed to practise in California · since 1986 · expires 2027-09-30 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$64,954
Medicare paid this office $64,954 for 165 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 140 | $45,775 | $118 |
| Long return visit (40+ min) | 20 | $4,891 | $169 |
| New patient visit (60+ min) | 24 | $3,918 | $163 |
| Return visit (30+ min) | 18 | $2,462 | $85 |
| Punch biopsy, first skin growth | 46 | $2,108 | $39 |
See all 7 services
| Long return visit (40+ min) | 140 | $45,775 | $118 |
| Long return visit (40+ min) | 20 | $4,891 | $169 |
| New patient visit (60+ min) | 24 | $3,918 | $163 |
| Return visit (30+ min) | 18 | $2,462 | $85 |
| Punch biopsy, first skin growth | 46 | $2,108 | $39 |
| Punch biopsy, each additional skin growth | 31 | $1,056 | $22 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 36 | $749 | $15 |
Procedures Medicare counted
| Removal of skin lesions | 14 | More than 61% of doctors who do this |
| Skin biopsy | 66 | More than 72% of doctors who do this |
Who their Medicare patients are
165 Original Medicare patients in 2024. Average age 76 · Women 52% · Also on Medicaid 15% · Health risk score 1.86. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 65% · Coronary heart disease 28% · Diabetes 25% · Chronic kidney disease 22% · Cancer 19% · Atrial fibrillation 19% · Depression 15% · COPD 14% · Heart failure 10%.
The office billed $188,338, Medicare allowed $88,323 and paid $64,954; for 717 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 165 | 717 | 76 | 1.86 | $188,338 | $64,954 |
| 2023 | 148 | 592 | 76 | 1.62 | $146,419 | $60,482 |
| 2022 | 172 | 653 | 76 | 1.58 | $159,052 | $61,793 |
| 2021 | 185 | 787 | 75 | 1.57 | $205,043 | $77,757 |
| 2020 | 179 | 819 | 75 | 1.84 | $223,079 | $64,889 |
| 2019 | 190 | 786 | 74 | 1.79 | $120,928 | $62,483 |
| 2018 | 210 | 876 | 74 | 1.74 | $104,919 | $65,251 |
| 2017 | 184 | 802 | 74 | 1.66 | $150,922 | $60,080 |
| 2016 | 177 | 687 | 73 | 1.63 | $148,529 | $49,255 |
| 2015 | 186 | 807 | 73 | 1.59 | $166,689 | $54,879 |
| 2014 | 168 | 682 | 74 | 1.65 | $146,182 | $48,195 |
| 2013 | 142 | 631 | 73 | 1.55 | $141,382 | $42,671 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Long return visit (40+ min) | 137 | $49,595 | $122 |
| Return visit (30+ min) | 23 | $4,336 | $85 |
| Punch biopsy, first skin growth | 37 | $2,046 | $44 |
| New patient visit (60+ min) | 12 | $2,004 | $167 |
| Punch biopsy, each additional skin growth | 22 | $853 | $24 |
2022: 6 services
| Long return visit (40+ min) | 151 | $47,988 | $116 |
| Return visit (30+ min) | 31 | $4,055 | $83 |
| New patient visit (60+ min) | 24 | $3,838 | $160 |
| Punch biopsy, first skin growth | 50 | $2,308 | $40 |
| Punch biopsy, each additional skin growth | 33 | $1,109 | $23 |
| Destruction of precancer skin growth, 1 growth | 11 | $657 | $51 |
2021: 6 services
| Long return visit (40+ min) | 160 | $58,341 | $120 |
| Return visit (30+ min) | 50 | $9,572 | $83 |
| New patient visit (60+ min) | 26 | $4,324 | $166 |
| Punch biopsy, first skin growth | 42 | $1,876 | $41 |
| Punch biopsy, each additional skin growth | 31 | $897 | $23 |
| Destruction of precancer skin growth, 1 growth | 11 | $600 | $46 |
2020: 7 services
| Long return visit (40+ min) | 148 | $43,091 | $98 |
| Return visit (30+ min) | 47 | $7,483 | $72 |
| New patient visit (60+ min) | 27 | $4,237 | $157 |
| Punch biopsy, first skin growth | 51 | $2,669 | $46 |
| Long return visit (40+ min) | 24 | $2,581 | $99 |
| Punch biopsy, each additional skin growth | 43 | $1,517 | $25 |
| Destruction of precancer skin growth, 1 growth | 12 | $800 | $50 |
2019: 5 services
| Long return visit (40+ min) | 162 | $42,911 | $95 |
| Return visit (30+ min) | 29 | $6,746 | $69 |
| New patient visit (60+ min) | 34 | $5,164 | $152 |
| Punch biopsy, first skin growth | 66 | $3,819 | $43 |
| Punch biopsy, each additional skin growth | 56 | $1,887 | $24 |
2018: 7 services
| Long return visit (40+ min) | 169 | $43,092 | $91 |
| Return visit (30+ min) | 41 | $10,345 | $65 |
| New patient visit (60+ min) | 39 | $5,304 | $136 |
| Biopsy of single growth of skin and/or tissue | 59 | $2,942 | $41 |
| Biopsy of each additional growth of skin and/or tissue | 43 | $1,213 | $22 |
| Short return visit (20+ min) | 13 | $671 | $42 |
| Destruction of precancer skin growth, 1 growth | 11 | $395 | $36 |
2017: 8 services
| Long return visit (40+ min) | 151 | $40,429 | $96 |
| Return visit (30+ min) | 34 | $8,228 | $69 |
| New patient visit (60+ min) | 25 | $3,606 | $144 |
| Biopsy of single growth of skin and/or tissue | 48 | $2,381 | $38 |
| Short return visit (20+ min) | 15 | $1,826 | $45 |
| New patient visit (45+ min) | 11 | $1,132 | $103 |
| Biopsy of each additional growth of skin and/or tissue | 28 | $886 | $21 |
| Destruction of precancer skin growth, 1 growth | 11 | $792 | $50 |
2016: 8 services
| Long return visit (40+ min) | 139 | $33,395 | $91 |
| Return visit (30+ min) | 23 | $4,903 | $69 |
| New patient visit (60+ min) | 33 | $4,608 | $140 |
| Biopsy of single growth of skin and/or tissue | 58 | $2,898 | $43 |
| Biopsy of each additional growth of skin and/or tissue | 38 | $1,134 | $23 |
| Destruction of precancer skin growth, 1 growth | 12 | $887 | $47 |
| Short return visit (20+ min) | 12 | $729 | $46 |
| Destruction of precancer skin growth, 2-14 growths | 11 | $107 | $2 |
2015: 8 services
| Long return visit (40+ min) | 141 | $36,928 | $92 |
| New patient visit (60+ min) | 46 | $6,600 | $143 |
| Return visit (30+ min) | 27 | $3,541 | $67 |
| Biopsy of single growth of skin and/or tissue | 65 | $3,186 | $40 |
| Destruction of precancer skin growth, 1 growth | 19 | $1,675 | $48 |
| Biopsy of each additional growth of skin and/or tissue | 36 | $1,118 | $22 |
| Short return visit (20+ min) | 13 | $856 | $45 |
| Destruction of precancer skin growth, 2-14 growths | 17 | $241 | $2 |
2014: 8 services
| Long return visit (40+ min) | 135 | $33,542 | $92 |
| Return visit (30+ min) | 26 | $3,847 | $69 |
| New patient visit (60+ min) | 26 | $3,774 | $145 |
| Biopsy of single growth of skin and/or tissue | 67 | $3,290 | $42 |
| Biopsy of each additional growth of skin and/or tissue | 39 | $1,197 | $22 |
| Destruction of precancer skin growth, 1 growth | 16 | $1,111 | $44 |
| Short return visit (20+ min) | 11 | $549 | $39 |
| Destruction of precancer skin growth, 2-14 growths | 13 | $112 | $2 |
2013: 7 services
| Long return visit (40+ min) | 101 | $26,141 | $89 |
| Return visit (30+ min) | 27 | $3,929 | $68 |
| New patient visit (60+ min) | 28 | $3,811 | $136 |
| Biopsy of single growth of skin and/or tissue | 61 | $3,368 | $41 |
| Destruction of precancer skin growth, 1 growth | 15 | $1,179 | $54 |
| Biopsy of each additional growth of skin and/or tissue | 35 | $1,173 | $22 |
| Short return visit (20+ min) | 11 | $659 | $44 |
Drugs they prescribed that Part D paid
$588,408
Pharmacies billed $588,408 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
807 generic and 84 brand-name prescriptions · $588,408 in drug cost · 46 antibiotic prescriptions to 32 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Bexarotene | 39 | $101,278 | $2,597 |
| Opzelura | 18 | $39,154 | $2,175 |
| Rasuvo | 34 | $18,152 | $534 |
| Acitretin | 51 | $15,080 | $296 |
| Clobetasol Propionate | 55 | $3,262 | $59 |
See all 19 drugs
| Bexarotene | 39 | $101,278 | $2,597 |
| Opzelura | 18 | $39,154 | $2,175 |
| Rasuvo | 34 | $18,152 | $534 |
| Acitretin | 51 | $15,080 | $296 |
| Clobetasol Propionate | 55 | $3,262 | $59 |
| Valacyclovir | 40 | $2,722 | $68 |
| Triamcinolone Acetonide | 92 | $1,670 | $18 |
| Isotretinoin | 12 | $1,434 | $120 |
| Methotrexate | 52 | $1,194 | $23 |
| Gabapentin | 46 | $966 | $21 |
| Cephalexin | 31 | $656 | $21 |
| Mupirocin | 74 | $536 | $7 |
| Hydrocortisone | 50 | $530 | $11 |
| Acyclovir | 11 | $393 | $36 |
| Prednisone | 34 | $367 | $11 |
| Atorvastatin | 16 | $295 | $18 |
| Ketoconazole | 13 | $281 | $22 |
| Hydroxyzine | 19 | $251 | $13 |
| Ondansetron | 12 | $63 | $5 |
Year by year
| 2024 | 891 | 133 | None | 9% | $588,408 |
| 2023 | 814 | 103 | 0% (0) | None | $688,729 |
| 2022 | 713 | 115 | 0% (0) | 7% | $506,085 |
| 2021 | 847 | 130 | 0% (0) | None | $555,568 |
| 2020 | 642 | 112 | None | None | $938,373 |
| 2019 | 719 | 121 | None | 13% | $1,212,403 |
| 2018 | 656 | 113 | 0% (0) | 17% | $1,339,468 |
| 2017 | 530 | 98 | None | 17% | $1,384,464 |
| 2016 | 386 | 97 | None | 27% | $769,593 |
| 2015 | 652 | 99 | None | 29% | $1,768,475 |
| 2014 | 468 | 77 | None | 22% | $693,274 |
| 2013 | 328 | 61 | None | 7% | $44,258 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Bexarotene | 59 | $410,858 | $6,964 |
| Valchlor | 19 | $112,578 | $5,925 |
| Opzelura | 13 | $28,837 | $2,218 |
| Aprepitant | 11 | $26,900 | $2,445 |
| Acitretin | 37 | $20,683 | $559 |
| Rasuvo | 16 | $10,424 | $652 |
| Clobetasol Propionate | 54 | $3,571 | $66 |
| Methotrexate | 57 | $2,976 | $52 |
| Tacrolimus | 15 | $2,643 | $176 |
| Triamcinolone Acetonide | 99 | $2,608 | $26 |
| Mupirocin | 75 | $935 | $12 |
| Cephalexin | 21 | $776 | $37 |
| Gabapentin | 29 | $666 | $23 |
| Levothyroxine | 24 | $657 | $27 |
| Valacyclovir | 11 | $562 | $51 |
| Prednisone | 36 | $250 | $7 |
| Atorvastatin | 12 | $244 | $20 |
| Hydrocortisone | 34 | $208 | $6 |
| Methotrexate | 12 | $178 | $15 |
| Ondansetron | 12 | $154 | $13 |
| Folic Acid | 24 | $52 | $2 |
2022: 15 drugs
| Bexarotene | 28 | $265,829 | $9,494 |
| Valchlor | 31 | $163,893 | $5,287 |
| Acitretin | 53 | $34,112 | $644 |
| Clobetasol Propionate | 60 | $8,627 | $144 |
| Triamcinolone Acetonide | 108 | $2,254 | $21 |
| Methotrexate | 56 | $1,721 | $31 |
| Fluocinonide | 14 | $1,177 | $84 |
| Gabapentin | 38 | $941 | $25 |
| Hydroxyzine | 27 | $747 | $28 |
| Mupirocin | 56 | $729 | $13 |
| Levothyroxine | 23 | $588 | $26 |
| Cephalexin | 20 | $573 | $29 |
| Atorvastatin | 16 | $418 | $26 |
| Hydrocortisone | 32 | $395 | $12 |
| Prednisone | 33 | $332 | $10 |
2021: 19 drugs
| Bexarotene | 26 | $273,883 | $10,534 |
| Valchlor | 35 | $197,090 | $5,631 |
| Acitretin | 56 | $25,716 | $459 |
| Clobetasol Propionate | 92 | $7,697 | $84 |
| Triamcinolone Acetonide | 126 | $3,390 | $27 |
| Methotrexate | 47 | $2,892 | $62 |
| Halobetasol Propionate | 11 | $1,625 | $148 |
| Gabapentin | 37 | $1,297 | $35 |
| Betamethasone Dipropionate | 13 | $1,228 | $94 |
| Mirtazapine | 13 | $1,193 | $92 |
| Mupirocin | 77 | $780 | $10 |
| Levothyroxine | 26 | $687 | $26 |
| Atorvastatin | 27 | $477 | $18 |
| Cephalexin | 25 | $471 | $19 |
| Acyclovir | 13 | $440 | $34 |
| Prednisone | 38 | $403 | $11 |
| Hydroxyzine | 25 | $314 | $13 |
| Sulfamethoxazole-Trimethoprim | 11 | $248 | $23 |
| Hydrocortisone | 38 | $214 | $6 |
2020: 16 drugs
| Bexarotene | 11 | $527,200 | $47,927 |
| Valchlor | 51 | $264,237 | $5,181 |
| Acitretin | 29 | $13,335 | $460 |
| Clobetasol Propionate | 67 | $5,230 | $78 |
| Triamcinolone Acetonide | 92 | $2,432 | $26 |
| Methotrexate | 41 | $2,219 | $54 |
| Gabapentin | 49 | $1,479 | $30 |
| Mirtazapine | 12 | $1,381 | $115 |
| Fluocinonide | 12 | $770 | $64 |
| Hydroxyzine | 25 | $722 | $29 |
| Mupirocin | 47 | $536 | $11 |
| Cephalexin | 18 | $328 | $18 |
| Prednisone | 33 | $293 | $9 |
| Levothyroxine | 14 | $265 | $19 |
| Valacyclovir | 12 | $141 | $12 |
| Hydrocortisone | 26 | $135 | $5 |
2019: 16 drugs
| Valchlor | 36 | $154,846 | $4,301 |
| Acitretin | 59 | $27,037 | $458 |
| Clobetasol Propionate | 53 | $4,058 | $77 |
| Gabapentin | 59 | $2,628 | $45 |
| Triamcinolone Acetonide | 91 | $2,299 | $25 |
| Halobetasol Propionate | 15 | $1,719 | $115 |
| Mirtazapine | 24 | $1,501 | $63 |
| Methotrexate | 22 | $1,211 | $55 |
| Hydroxyzine | 17 | $655 | $39 |
| Levothyroxine | 36 | $449 | $12 |
| Cephalexin | 26 | $424 | $16 |
| Prednisone | 46 | $414 | $9 |
| Acyclovir | 21 | $384 | $18 |
| Mupirocin | 34 | $325 | $10 |
| Hydrocortisone | 31 | $180 | $6 |
| Atorvastatin | 14 | $96 | $7 |
2018: 20 drugs
| Actimmune | 11 | $572,898 | $52,082 |
| Bexarotene | 14 | $433,706 | $30,979 |
| Valchlor | 36 | $141,003 | $3,917 |
| Acitretin | 23 | $10,290 | $447 |
| Clobetasol Propionate | 64 | $8,809 | $138 |
| Triamcinolone Acetonide | 98 | $2,309 | $24 |
| Betamethasone Dipropionate | 16 | $1,738 | $109 |
| Gabapentin | 40 | $1,369 | $34 |
| Methotrexate | 23 | $814 | $35 |
| Desonide | 11 | $611 | $56 |
| Mirtazapine | 18 | $610 | $34 |
| Mupirocin | 31 | $529 | $17 |
| Acyclovir | 28 | $489 | $17 |
| Cephalexin | 19 | $484 | $25 |
| Mometasone Furoate | 11 | $437 | $40 |
| Levothyroxine | 26 | $361 | $14 |
| Atorvastatin | 16 | $248 | $16 |
| Sulfamethoxazole-Trimethoprim | 17 | $209 | $12 |
| Prednisone | 19 | $160 | $8 |
| Hydrocortisone | 12 | $124 | $10 |
2017: 14 drugs
| Actimmune | 11 | $549,422 | $49,947 |
| Bexarotene | 14 | $469,487 | $33,535 |
| Valchlor | 48 | $190,636 | $3,972 |
| Clobetasol Propionate | 67 | $13,511 | $202 |
| Acitretin | 12 | $9,039 | $753 |
| Methotrexate | 32 | $1,927 | $60 |
| Triamcinolone Acetonide | 62 | $1,242 | $20 |
| Gabapentin | 29 | $779 | $27 |
| Mirtazapine | 16 | $548 | $34 |
| Atorvastatin | 23 | $473 | $21 |
| Levothyroxine | 24 | $401 | $17 |
| Mupirocin | 32 | $327 | $10 |
| Cephalexin | 19 | $297 | $16 |
| Prednisone | 11 | $137 | $12 |
2016: 8 drugs
| Valchlor | 71 | $265,679 | $3,742 |
| Clobetasol Propionate | 73 | $19,271 | $264 |
| Triamcinolone Acetonide | 32 | $878 | $27 |
| Methotrexate | 21 | $837 | $40 |
| Mupirocin | 28 | $337 | $12 |
| Cephalexin | 17 | $294 | $17 |
| Atorvastatin | 11 | $226 | $21 |
| Hydroxyzine | 14 | $177 | $13 |
2015: 17 drugs
| Targretin | 24 | $814,941 | $33,956 |
| Valchlor | 129 | $467,358 | $3,623 |
| Bexarotene | 11 | $330,877 | $30,080 |
| Clobetasol Propionate | 100 | $34,226 | $342 |
| Methotrexate | 34 | $2,950 | $87 |
| Desonide | 18 | $2,019 | $112 |
| Triamcinolone Acetonide | 40 | $1,146 | $29 |
| Gabapentin | 38 | $1,080 | $28 |
| Mirtazapine | 19 | $624 | $33 |
| Mometasone Furoate | 17 | $568 | $33 |
| Valacyclovir | 16 | $566 | $35 |
| Mupirocin | 31 | $499 | $16 |
| Cephalexin | 30 | $395 | $13 |
| Sulfamethoxazole-Trimethoprim | 14 | $332 | $24 |
| Levothyroxine | 20 | $266 | $13 |
| Atorvastatin | 16 | $168 | $10 |
| Hydroxyzine | 11 | $147 | $13 |
2014: 12 drugs
| Targretin | 15 | $439,565 | $29,304 |
| Valchlor | 43 | $197,137 | $4,585 |
| Clobetasol Propionate | 73 | $8,967 | $123 |
| Desonide | 22 | $2,770 | $126 |
| Gabapentin | 45 | $1,259 | $28 |
| Triamcinolone Acetonide | 38 | $1,247 | $33 |
| Cephalexin | 36 | $652 | $18 |
| Methotrexate | 11 | $608 | $55 |
| Mometasone Furoate | 14 | $490 | $35 |
| Mupirocin | 32 | $415 | $13 |
| Sulfamethoxazole-Trimethoprim | 20 | $284 | $14 |
| Levothyroxine | 14 | $145 | $10 |
2013: 8 drugs
| Clobetasol Propionate | 62 | $2,959 | $48 |
| Desonide | 14 | $2,210 | $158 |
| Fluocinonide | 17 | $1,290 | $76 |
| Gabapentin | 43 | $1,228 | $29 |
| Triamcinolone Acetonide | 36 | $1,061 | $29 |
| Cephalexin | 15 | $308 | $21 |
| Mupirocin | 17 | $275 | $16 |
| Levothyroxine | 12 | $85 | $7 |
Money from drug and device companies
$6,093 in 2025
| 2025 | 2 | 5 | $5,475 | $6,093 |
| 2023 | 1 | 3 | None | $570 |
| 2022 | 2 | 3 | $7,758 | $7,758 |
| 2021 | 1 | 1 | $1,482 | $1,482 |
| 2020 | 2 | 2 | $3,680 | $3,680 |
| 2019 | 3 | 27 | $34,255 | $39,548 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Kyowa Kirin | Poteligeo | $6,037 | 4 payments
|
| Kyowa Kirin Services | Poteligeo | $56 | 1 payment
|
See all 5 published payments
| Kyowa Kirin | Consulting · 2025-11-04 | Poteligeo | $4,380 |
| Kyowa Kirin Services | Meals · 2025-10-17 | Poteligeo | $56 |
| Kyowa Kirin | Meals · 2025-10-15 | Poteligeo | $74 |
| Kyowa Kirin | Travel · 2025-10-14 | Poteligeo | $488 |
| Kyowa Kirin | Consulting · 2025-06-12 | Poteligeo | $1,095 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $570
| Kyowa Kirin | Poteligeo | $570 | 3 payments
|
2022: $7,758
| Kyowa Kirin | Poteligeo | $4,733 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $3,025 | 1 payment
|
2021: $1,482
| Almirall | None | $1,482 | 1 payment
|
2020: $3,680
| Kyowa Kirin | Poteligeo | $3,030 | 1 payment
|
| Almirall | None | $650 | 1 payment
|
2019: $39,548
| Kyowa Kirin | Poteligeo | $31,823 | 24 payments
|
| Kyowa Kirin Services | Poteligeo | $4,725 | 1 payment
|
| Almirall | None | $3,000 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Kyowa Kirin, Inc. · A Phase 2 Single?Center, Single?Arm, Open?Label Mogamulizumab Combined Upfront With Low?Dose Total Skin Electron Beam Therapy (Ld?Tsebt) in Patients With Mycosis Fungoides (Mf) and S?Zary Syndrome (Ss) · 2020 | Their institution | $323,387 |
| Innate Pharma, Inc · An Open Label, Multicohort, Multi-Center Phase II Study Evaluating the Efficacy and Safety of Iph4102/Lacutamab Alone Or in Combination With Chemotherapy in Patients With Advanced T-Cell Lymphoma · 2020 | Their institution | $221,523 |
| KYOWA KIRIN, INC. · A Phase 2 Single-Center, Single-Arm, Open-Label Mogamulizumab Combined Upfornt With Low-Dose Total Skin Electron Beam Therapy · 2025 | Their institution | $133,195 |
| PORTOLA PHARMACEUTICALS, INC. · Curdulatinib · 2019 | Their institution | $126,757 |
| Innate Pharma, Inc · Open Label, Multicenter Phase I Study of Iph4102, A Humanized Anti-Kir3dl2 Monoclonal Antibody, in Patients With Relapsed/Refractory Cutaneous T-Cell Lymphomas (Ctcl) · 2020 | Their institution | $113,264 |
| Kyowa Kirin, Inc. · Open-Label, Phase 2 Study To Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (Ctcl) · 2023 | Their institution | $111,201 |
| Eisai Inc. · A Clinical Study To Demonstrate Safety and Efficacy of E7777 in Persistent Or Recurrent Cutaneous T-Cell Lymphoma · 2022 | Their institution | $110,301 |
| Kyowa Kirin, Inc. · Open-Label, Phase 2 Study To Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (Ctcl) · 2022 | Their institution | $85,673 |
| Kyowa Kirin, Inc. · Open-Label, Phase 2 Study To Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (Ctcl) · 2024 | Their institution | $61,106 |
| Eisai Inc. · A Clinical Study To Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent Or Recurrent Cutaneous T-Cell Lymphoma · 2020 | Their institution | $45,474 |
| Eisai Inc. · A Clinical Study To Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent Or Recurrent Cutaneous T-Cell Lymphoma · 2019 | Their institution | $37,776 |
| KYOWA KIRIN, INC. · Open-Label, Phase 2 Study To Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (Ctcl) · 2025 | Their institution | $30,295 |
| PFIZER INC. · An Openlabel Phase 1 Study To Evaluate the Safety of Sgn35t in Adults With Advanced Malignancies · 2024 | Their institution | $27,060 |
| Alexion Pharmaceuticals, Inc. · A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (Prt062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (Cll)/Small Lymphocytic Lymphoma (Sll) Or B Cell Or T Cell Non-Hodgkin Lymphoma (Nhl) · 2021 | Their institution | $21,322 |
| Kyowa Kirin Pharmaceutical Development, Inc · Open-Label, Multi-Center, Randomized Study of Anti-Ccr4 Monoclonal Antibody Kw-0761 Mogamulizumab Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma · 2019 | Their institution | $15,361 |
| Eisai Inc. · A Clinical Study To Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent Or Recurrent Cutaneous T-Cell Lymphoma · 2021 | Their institution | $14,632 |
| PORTOLA PHARMACEUTICALS, LLC · 2020 | Their institution | $1,920 |
| PFIZER INC. · Nirogacestat Clinical Publication Program · 2024 | This clinician | $940 |
| PFIZER INC. · Pf06647263 Clinical Publication Program · 2024 | This clinician | $330 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1770619355
- Licence
- CA G58071California G58071: Current · expires 2027-09-30
- Trained
- Stanford University School of Medicine, 1984
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G580710
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-26
- NPI last updated
- 2026-09-02
- NPI record certified
- 2026-09-02
This is when the NPI record was last certified, not a medical board exam.